Vonvendi has been approved to treat adults with von Willebrand disease (VWD), the most common inherited bleeding disorder.
VWD, affecting about 1 percent of the U.S. population, is caused by lack of a protein that’s essential for blood clotting. People with the disorder can develop severe bleeding from the nose, gums, intestines, muscles and joints. Women with VWD also can bleed excessively after a menstrual period or after giving birth.
Vonvendi, a genetically engineered (recombinant) form of the missing protein, was evaluated in clinical studies of 69 adults with VWD. Itching was the most common side effect, the FDA said Tuesday in a news release.
Vonvendi is produced by Baxalta, based in Westlake Village, Calif.
Visit the FDA to learn more.